Durvalumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Durvalumab and local guidelines before prescribing.
Immune checkpoint inhibitor
Mechanism
PD-L1 inhibitor.
Uses
Lung cancer, biliary tract cancer, hepatocellular carcinoma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related pneumonitis, hepatitis, colitis, endocrinopathies.
Interactions
Steroids reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
TFT, LFT, cortisol
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Early identification and steroid treatment of immune toxicity.
More from the textbook: uses, cautions and other points
- Mechanism: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) release the brakes on the immune system. As well as attacking the cancer, they can cause immune-related adverse events in almost any organ - at any time, even months after stopping.
Respiratory: Lung Cancer - Atezolizumab plus bevacizumab , or durvalumab plus tremelimumab (first line).
Gastroenterology: Cirrhosis and Transplantation - Usually concurrent chemoradiotherapy , followed by durvalumab (immunotherapy) for a year if PD-L1-positive.
Respiratory: Lung Cancer - Platinum-etoposide chemotherapy plus immunotherapy ( atezolizumab or durvalumab), then maintenance immunotherapy.
Respiratory: Lung Cancer - Durvalumab | Immunotherapy after chemoradiotherapy for stage III NSCLC; with chemotherapy in small cell lung cancer.
Respiratory: Lung Cancer - Early NSCLC: surgery or SABR. Stage III: chemoradiotherapy then durvalumab. Stage IV: targeted therapy for mutations, otherwise immunotherapy with or without chemotherapy.
Respiratory: Lung Cancer - Gemcitabine and cisplatin with durvalumab (or pembrolizumab).
Gastroenterology: Pancreas and Biliary - Gemcitabine + cisplatin + durvalumab | Advanced cholangiocarcinoma and gallbladder cancer.
Gastroenterology: Pancreas and Biliary
Where it is discussed in the book
- Respiratory: Lung Cancer (5 mentions)
- Gastroenterology: Pancreas and Biliary (2 mentions)
- Gastroenterology: Cirrhosis and Transplantation (1 mention)
- Oncology: Principles (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (5 mentions)